December 6th, 2011
More enforcement and bigger fines may change illegal drug marketing, say Harvard researchers
By Susan Todd
The nation’s pharmaceutical industry will have to be threatened with stiffer penalties and greater enforcement efforts before companies end their inappropriate marketing tactics, according to a study released yesterday by a group of researchers at Harvard Medical School.
Using Pfizer’s anti-seizure drug Neurontin as an example, the researchers tracked prescription-writing activity from the first public indication of a federal investigation through the time of the company’s ultimate settlement with authorities in 2004 over a practice known in the industry as off-label marketing.
Read more: http://bit.ly/rCfj2o